MyNorthwest

News

Opinion

Sports

Tools

Connect

Novavax hopes its COVID shot wins over FDA, vaccine holdouts

In this image provided by the Serum Institute of India, vials of freshly manufactured Novavax COVID-19 vaccines wait to be labeled in 2022, in Pune, India. The U.S. Food and Drug Administration is evaluating a more traditional kind of vaccine made by Novavax, which the company hopes can win over unvaccinated people and become a top choice for boosters. (Serum Institute of India for Novavax via AP)

Novavax research chief Dr. Gregory Glenn discusses the company’s COVID-19 vaccine in Gaithersburg, Md., on May 24, 2022. The U.S. Food and Drug Administration is evaluating a more traditional kind of vaccine made by Novavax, which the company hopes can win over unvaccinated people and become a top choice for boosters. (AP Photo/Angie Wang)

Scientists examine a step in the vaccine purification process as they design updates to the Novavax's COVID-19 shots in the company's research laboratory on May 24, 2022, in Gaithersburg, Md. The U.S. Food and Drug Administration is deciding whether to authorize use of Novavax’s more traditional kind of COVID-19 vaccine, which the company hopes can win over unvaccinated people and become a top choice for boosters. (AP Photo/Angie Wang)

Scientists work on the vaccine purification process as they design updates to the Novavax's COVID-19 shots in the company's research laboratory on May 24, 2022, in Gaithersburg, Md. The U.S. Food and Drug Administration is deciding whether to authorize use of Novavax’s more traditional kind of COVID-19 vaccine, which the company hopes can win over unvaccinated people and become a top choice for boosters. (AP Photo/Angie Wang)

Novovax COVID-19 vaccine's incubate in flasks at the company research laboratory in Gaithersburg, Md., on May 24, 2022. The company is hoping to find a niche among some of the unvaccinated millions who might agree to their more traditional protein vaccine as a shot. (AP Photo/Angie Wang)

Novavax hopes its COVID shot wins over FDA, vaccine holdouts